Literature DB >> 3155767

Graft-vs-host reactions (GVHR) across minor murine histocompatibility barriers. I. Impairment of mitogen responses and suppressor phenomena.

J H Holda, T Maier, H N Claman.   

Abstract

In our laboratory, we have developed a murine model to examine GVHD across minor histocompatibility antigens. In our model, GVHD is induced by injecting B10.D2 spleen cells into irradiated BALB/c recipients. Seven to 10 days after irradiation and injection of cells, there are significant changes in cell function in the recipient spleens. In the B10.D2----BALB/c (600 rad) model, recipient spleen cells are profoundly unresponsive to Con A and LPS stimulation but show increased B cell activity measured by Staphylococcus aureus protein A plaque-forming activity. Spleen cells from such GVH mice profoundly suppress the mitogenic responses of normal BALB/c or B10.D2 spleen cells to Con A and LPS. The degree of impairment of the mitogenic response and the ability to suppress normal cells is proportional to the dose of cells used to induce GVH reactions. Both the inability to respond to mitogens and the capacity to suppress are also related to the dose of irradiation given to the recipients. In addition, immunosuppression across minor histocompatibility antigens shows an unevenhandedness. If we inject parental B10.D2 or BALB/c cells into F1 recipients (P----F1), there is greater inhibition of mitogenic responses when B10.D2 parental cells are given than when BALB/c cells are given to the irradiated F1 recipients. These experiments show that significant immunosuppression occurs during GVH reactions across minor histocompatibility barriers. The degree of suppression varies according to the dose of cells used to induce GVH, the dose of irradiation to the recipient and the "strength" of the GVH recognition system. Such experiments provide models for GVH disease seen in humans who receive treatment for leukemia or other diseases that involves recipient irradiation and infusion of HLA-identical bone marrow.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3155767

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  6 in total

1.  Lymphokine activity production in graft-versus-host reactions across minor histocompatibility antigen barriers.

Authors:  M Hirokawa; H Takatsu; A Ohshima; A Chubachi; K Kudo; H Niitsu; T Takahashi; K Yoshida; A B Miura
Journal:  Clin Exp Immunol       Date:  1989-09       Impact factor: 4.330

2.  A study on type II collagen-induced arthritis in allogeneic bone marrow chimaeras.

Authors:  M Fujita; M Mishima; K Iwabuchi; C Katsume; T Gotohda; K Ogasawara; Y Mizuno; R A Good; K Onoé
Journal:  Immunology       Date:  1989-03       Impact factor: 7.397

3.  Dynamic change and impact of myeloid-derived suppressor cells in allogeneic bone marrow transplantation in mice.

Authors:  Dapeng Wang; Yu Yu; Kelley Haarberg; Jianing Fu; Kane Kaosaard; Srinivas Nagaraj; Claudio Anasetti; Dmitry Gabrilovich; Xue-Zhong Yu
Journal:  Biol Blood Marrow Transplant       Date:  2013-01-30       Impact factor: 5.742

Review 4.  The Role and Potential Therapeutic Application of Myeloid-Derived Suppressor Cells in Allo- and Autoimmunity.

Authors:  Qi Zhang; Masayuki Fujino; Jinhua Xu; Xiao-kang Li
Journal:  Mediators Inflamm       Date:  2015-05-19       Impact factor: 4.711

Review 5.  Myeloid-Derived Suppressor Cells in the Context of Allogeneic Hematopoietic Stem Cell Transplantation.

Authors:  Maud D'Aveni; Anne B Notarantonio; Allan Bertrand; Laura Boulangé; Cécile Pochon; Marie T Rubio
Journal:  Front Immunol       Date:  2020-05-22       Impact factor: 7.561

6.  Synergism between T and non-T cells in the in vivo induction and in vitro expression of graft-vs.-host disease-induced natural suppressor cells.

Authors:  T Maier; J H Holda; H N Claman
Journal:  J Exp Med       Date:  1985-09-01       Impact factor: 14.307

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.